Intrepida Bio

Intrepida Bio, founded by its co-founder and CEO Dr. Joel F. Martin, Chief Scientific Officer Dr. Olivier Laurent, and Biouniversa srl (the academic branch operating in the biotechnology field in Campania), is headquartered in San Diego, California, USA. The company is dedicated to developing novel drugs that modulate the innate immune system to combat cancer and other diseases. Intrepida Bio has designed proprietary monoclonal antibodies that block the novel target BAG3 and its receptor IFITM-2 to disrupt their ability to create a favorable environment for tumor growth.